Efficacy and Safety of Interferon Alpha-2b in COVID-19: A Systematic Review-Reference-Cited by-同舟云学术

Efficacy and Safety of Interferon Alpha-2b in COVID-19: A Systematic Review

Published:2022-03-31 Issue:1 Volume:15 Page:27-32
ISSN:2456-2610
Container-title:Biomedical and Pharmacology Journal
language:en
Short-container-title:Biomed. Pharmacol. J.

Author:

Kumar Subodh¹^ORCID,Saurabh Manoj Kumar¹^ORCID,Maharshi Vikas¹

Affiliation:

1. Department of Pharmacology, All India Institute of Medical Sciences, Deoghar-814142, India.

Abstract

Introduction Several drugs have been explored for the antiviral action against COVID-19 disease but none of them has been approved barring few such as Remdesivir which got emergency use authorization from USFDA. Interferon are attractive agents due to their broad anti-viral and immunological properties. Interferon alpha-2b has been recently investigated for this purpose. This study presents a systematic review of all the clinical studies involving Interferon alpha-2b to determine its efficacy and safety. Methods A systematic review of literature was done using relevant terms for ‘COVID-19” and “Interferon alpha”. The studies evaluating the effect of Interferon alpha were identified and included in the study for qualitative analysis. Result and Discussion All four clinical studies have shown that Interferon alpha 2b has efficacy as antiviral agent as shown by different clinical and laboratory parameters. It has also found to be safe and free of any major side effects. Conclusion Interferon alpha 2b is an effective antiviral agent with potential to be use in COVID-19. This drug has already been given restricted use authorization in India.

Publisher

Oriental Scientific Publishing Company

Subject

Pharmacology

Reference21 articles.

1. 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al., A novel Coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-33. (1056/NEJMoa2001017).

2. 2. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020 Mar 19;91(1):157-160.

3. 3. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect. 2020;80(6):656-665.

4. 4. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;323(18):1824-1836.

5. 5. Hinton R.D.M. 2020. Letter is in response to your request that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for emergency use of remdesivir for the treatment of hospitalized 2019 coronavirus disease (COVID-19) patients, pp. 1-6. Available at https://www.fda.gov/media/137564/download Accessed August 27, 2020.